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OBJECTIVES We sought to determine the relative prognostic power of several clinical and dobutamine
stress test variables in patients after a first uncomplicated acute myocardial infarction (AMI).
BACKGROUND The value of dobutamine echocardiography (DE) for determining prognosis after AMI is not
yet defined. In particular, the influence of dobutamine stress test response on the outcome of
these patients is unknown.
METHODS A graded predischarge DE (from 5 to 40 mg/kg/min, plus atropine if needed) was performed
in 245 patients (mean age 60 6 10 years) with a first uncomplicated AMI.
RESULTS At follow-up (17 6 13 months), an adverse outcome occurred in 40 patients: cardiac death
in 7, nonfatal myocardial infarction in 9 (hard events 5 16) and unstable angina requiring
hospital readmission in 24. Significant predictors of adverse outcome by univariate analysis
were positive DE, ischemic wall motion score index (WMSI), angina during DE and diabetes
for all events, and positive DE, ischemic WMSI and age for hard events. At multivariate
analysis, the only independent predictors of adverse outcome were positive DE, diabetes and
angina during DE for all events, and positive DE and age for hard events. The presence of
both age .60 years and a history of diabetes identified patients at high risk of cardiac events
(event rate 37%), compared with patients ,60 years and no diabetes (event rate 11%). In
patients with intermediate risk (only one clinical risk factor, event rate 18%), DE added
prognostic information (event rate 10% in the negatives, 25% in the positives and 35% in the
positives with angina).
CONCLUSIONS After uncomplicated AMI, dobutamine stress test variables offer additional prognostic
information to clinical data. (J Am Coll Cardiol 1999;34:435–40) © 1999 by the American
College of Cardiology
Prognostication of patients after acute myocardial infarction
(AMI) is still under debate. Clinical evaluation during
hospital stay allows identification of high-risk patients who
have complications and probably benefit from early angiog-
raphy. Patients at low risk can be identified from simple
clinical characteristics that include no evidence of heart
failure, no recurrent ischemia and a preserved left ventricular
(LV) function. Such patients have an overall good progno-
sis, with an expected one-year mortality of ,4%, and usually
undergo a predischarge stress testing to refine risk assess-
ment and to provide guidance for future management (1).
Over the last few years, dobutamine echocardiography
(DE) has been increasingly proposed for the diagnosis and
prognosis of patients with suspected or proven coronary
artery disease (2). We have recently found that dobutamine-
induced wall motion abnormalities provide similar prognos-
tic information to exercise induced S-T segment depression
in patients evaluated early after an uncomplicated AMI (3).
However, the additional information of DE beyond that
obtained by clinical data has not been explored. Further-
more, complementary information regarding LV function,
presence of myocardial viability, extent and severity of
myocardial ischemia, symptoms and electrocardiographic
(ECG) changes during dobutamine infusion can be ob-
tained during the dobutamine stress test, possibly enhancing
the diagnostic and prognostic capability of the test.
Accordingly, the purpose of this study was: 1) to analyze
the power of dobutamine stress test variables for predicting
cardiac events after an uncomplicated AMI; and 2) to
evaluate the additional prognostic information of dobut-
amine stress test beyond those obtained by clinical data only.
METHODS
Study group. This prospective study was carried out in 342
patients who were consecutively admitted to the coronary
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care unit at our institution for a first AMI. Diagnosis of
myocardial infarction was based on a consistent history,
ECG changes and cardiac enzyme level elevations. Patients
with early postinfarction angina (n 5 44), left ventricular
failure (n 5 38) or important cardiac arrhythmias (n 5 12)
were excluded from the study. Of the 248 patients fulfilling
the selection criteria, three had low-quality baseline echo-
cardiographic images making the DE unfeasible. Therefore,
the final study population consisted of 245 patients (mean
age 60 6 10 years; 210 males) with a clinically uncompli-
cated first AMI who were enrolled in a follow-up program.
Sixty-eight (28%) patients had a history of hypertension and
26 (11%) were diabetic. Thrombolysis was performed in 118
(48%) patients. The site of myocardial infarction was
anterior in 103 (42%), inferior in 114 (47%) and non-Q in
28 (11%) patients. After written informed consent, DE was
performed 1 to 2 days before hospital discharge (range 6 to
14 days after admission). Antianginal drugs were discontin-
ued (beta-adrenergic blocking agents for 36 h, nitrates and
calcium channel antagonist for 24 h).
Dobutamine echocardiography. Each patient underwent
DE using a standard protocol that has been described in
detail previously (3). Briefly, a two-dimensional trans-
thoracic echocardiogram in standard views was recorded at
rest and then dobutamine was infused, at dosages of 5 and
10 mg/kg/min for 5 min at each dose (these two steps were
considered as low-dose). Subsequently, three other steps
from 20 to 40 mg/kg/min for 3 min were added. Finally, in
patients not achieving 85% of their gender- and age-
predicted maximal heart rate and with no symptoms or signs
of myocardial ischemia, atropine (starting with 0.25 mg
increasing to a maximum of 1 mg) was injected, while
dobutamine was continued.
The test was prematurely terminated in the presence of
horizontal or downsloping S-T segment depression
.0.2 mV 80 ms after the J point, S-T segment elevation in
non-Q wave leads, serious cardiac arrhythmias, significant
chest pain, reduction in systolic blood pressure .40 mm Hg
from that at rest, a systolic blood pressure ,90 mm Hg,
hypertension (systolic blood pressure .220 mm Hg) or any
side effect regarded as being due to dobutamine. A new wall
motion abnormality was considered an interruption criteria
only if it occurred in more than two segments. Atenolol was
available and used (1 to 5 mg intravenously) to reverse the
effects of dobutamine or dobutamine-atropine combination
if these did not revert spontaneously and quickly.
A commercially available imaging system equipped with a
2.5-MHz probe was used for imaging. Left ventricular wall
motion was continuously monitored and the images were
recorded on video tape at rest and during the final minute of
each stage.
Echocardiographic images were analyzed off-line and a
consensus was achieved by two cardiologists blinded to
clinical data. For the wall motion analysis, the left ventricle
was divided into 16 segments (4) and each segment was
scored using a four-point scale, where: 1 5 normal, 2 5
hypokinesis, 3 5 akinesis and 4 5 dyskinesis. A global wall
motion score index (WMSI) was calculated at baseline, at
low and at high doses of dobutamine, dividing the sum of
each segments by the number of the segments. Infarct zones
for anterior and inferior infarcts were constructed according
to the theoretic maximal area at risk (5). The apical inferior
and apical lateral segments were considered to be overlap-
ping. Thus, each infarct zone comprised nine segments. An
infarct zone WMSI was calculated at baseline and during
low- and high-dose dobutamine, averaging the sum of the
individual scores in segments in the infarct zone by the
number of the segments. An infarct zone was judged to have
contractile reserve (comparing baseline WMSI with WMSI
at low dose dobutamine) when infarct zone WMSI de-
creased by $0.22 (5). An ischemic response was defined by
an increase in WMSI $0.22 in the infarct region (homo-
zonal ischemia) or in the noninfarcted region (remote
ischemia) in comparison with WMSI during low-dose
dobutamine. Ischemia was not considered when akinetic
segments at rest became dyskinetic at stress without im-
provement during low-dose infusion (6).
Electrocardiograms during dobutamine were reviewed by
an observer who was unaware of the results of DE; S-T
segment depression .1 mm was considered as a positive
ECG response.
Follow-up. Follow-up data were obtained in all patients
from routine follow-up visits in the outpatient cardiac clinic
at the Sandro Pertini Hospital or from a telephone interview
with the patient conducted by a staff cardiologist. We
determined the specific occurrence of cardiac events defined
as cardiac death, nonfatal recurrent infarction and readmis-
sion to the coronary care unit for control of unstable angina.
Description of causes and circumstances of death and the
definition of a new cardiac event have been described
elsewhere (3). Only the first event was considered for each
patient. Referral for cardiac catheterization and subsequent
therapeutic decisions were made by the patient’s physician
based on the results of exercise testing and/or because the
patients were symptomatic, and were independent of the
DE results. Follow-up of patients undergoing elective
revascularization procedures was concluded at the time of
revascularization, which was not considered a cardiac event
because the decision to perform these procedures might be
subjective.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
DE 5 dobutamine echocardiography
ECG 5 electrocardiogram, electrocardiographic
LV 5 left ventricular
WMSI 5 wall motion score index
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Statistical analysis. Results are expressed as mean value 6
SD for continuous variables and as percent for categorical
variables.
The predictive role of certain variables on event-free
survival was evaluated by the Cox proportional hazard
model using the forward selection stepwise procedure avail-
able in BMDP 2L statistical package (7). The clinical
variables consisted of age, gender, thrombolysis, Q-wave
myocardial infarction, anterior AMI, hypertension and
diabetes. The stress test variables included WMSI at rest,
WMSI at low dose, WMSI at peak stress, ischemic WMSI
(stress/rest WMSI variation), viability at low-dose dobut-
amine, positive DE, remote ischemia, dobutamine time (the
interval from the beginning of the test to the onset of
myocardial ischemia), S-T segment depression during do-
butamine and angina during dobutamine. In tests giving
negative results, the dobutamine time was arbitrarily as-
sumed to be 26 min.
Continuous variables were compared by the unpaired t
test. Proportions were compared by using the zeta test by
Remington. For multivariate analysis, data are expressed as
relative risk with 95% confidence intervals (CI). A p value
,0.05 was considered significant.
RESULTS
Dobutamine stress test. No serious complications were
noted during dobutamine infusion. Atropine was added to
dobutamine in 130 patients. The test was inconclusive
(negative echocardiogram at submaximal stress, i.e., peak
heart rate ,85% of maximal age predicted heart rate) in
four patients. The test results of these patients were in-
cluded in the analysis. The rate-pressure product at peak
stress was 19,422 6 3,469.
Myocardial viability was present at low dose of dobut-
amine in 73 patients (30%). Dobutamine echocardiography
was positive for myocardial ischemia in 115 patients (47%).
Among the patients with a positive result, 57 (50%) had a
positive finding after atropine administration. In 70 (61%)
patients, a worsening of wall motion appeared within the
infarct zone (homozonal ischemia), in 53 of these after an
improvement at low dose of dobutamine (biphasic re-
sponse). These 53 patients were similar in terms of clinical
or baseline echocardiographic findings to the 17 patients
with a direct worsening of wall motion. In the remaining 45
patients, new wall motion abnormalities were found in the
remote zone (remote ischemia). The mean time of echocar-
diographic positivity was 20.1 6 4.1 min.
Significant S-T segment depression occurred in 70 pa-
tients (29%) and angina in 47 (19%). Considering wall
motion abnormalities, S-T segment depression and angina
during dobutamine stress test as markers of myocardial
ischemia, 20 patients had 3 markers, 53 patients had 2
markers, 61 patients had 1 marker and 111 patients had no
marker of myocardial ischemia. The number of markers of
ischemia observed was not related to the peak dobutamine
dose or the dobutamine time.
Follow-up data. During the follow-up (mean 17 6 13
months, range 1 to 44 months), a total of 40 events
occurred: 7 deaths, 9 nonfatal AMIs (hard events, n 5 16)
and 24 unstable angina requiring hospital admission.
In Table 1, the results of DE are correlated with the
spontaneous events that occurred at follow-up evaluation. A
positive DE increases the risk of all and hard cardiac events
by 2.1- and 4.8-fold, respectively. Sensitivity, specificity and
positive and negative predictive values for all events were
65%, 57%, 23% and 89%, and for hard events, 81%, 55%,
11% and 98%, respectively.
The univariate prognostic factors for spontaneous events
are shown in Table 2. The most important predictors for all
events was the ischemic WMSI, and for hard events, the
positivity at DE. The event rate was similar in patients with
homozonal versus remote ischemia (24% vs. 20% for all
events; 13% vs. 9% for hard events).
By stepwise analysis, the predictors for all events were a
history of diabetes, DE positivity and the occurrence of
angina during DE. Considering hard events, the only
independent prognostic factors were age and DE positivity
(Fig. 1).
Predictive value of dobutamine stress test. The incidence
of cardiac events according to the number of ischemic
markers (wall motion abnormalities, angina and S-T seg-
ment changes) during dobutamine stress test is reported in
Figure 2. The results indicate that the higher the number of
ischemic markers during dobutamine stress test, the worse
the outcome of the patients. In particular, cardiac events
occurred in 19 of 73 patients with two or three markers of
myocardial ischemia, and in 21 of 171 patients with zero or
one marker of myocardial ischemia. The event rate was 26%
versus 12% (p , 0.01).
DISCUSSION
Dobutamine stress test after AMI. We have already
evaluated the relative merit of DE and exercise testing for
risk stratification early after AMI (3), and we found that the
presence of dobutamine-induced wall motion abnormalities
Table 1. Event Rate Occurrence in Relation to Dobutamine
Echocardiographic Results
DE1
(n 5 115)
DE2
(n 5 130)
No events (n 5 205) 89 (77%) 116 (89%)
All events (n 5 40) 26 (23%)* 14 (11%)
Hard events (n 5 16) 13 (11%)† 3 (2.3%)
Death (n 5 7) 5 (4%) 2 (1.5%)
Myocardial infarction (n 5 9) 8 (7%)† 1 (0.8%)
Unstable angina (n 5 24) 13 (11%) 11 (8%)
*p 5 0.05; †p , 0.01.
DE 5 dobutamine echocardiography; 1 5 positive; 2 5 negative.
437JACC Vol. 34, No. 2, 1999 Salustri et al.
August 1999:435–40 Dobutamine Stress Test After Myocardial Infarction
gives prognostic information similar or even better than
exercise-induced S-T segment depression. However, com-
plementary information can be obtained from other vari-
ables that can be monitored during dobutamine stress
testing, the presence of myocardial viability at a low dose of
dobutamine and the occurrence of ECG changes or angina.
The results of the present study can be summarized as
follows:
1) dobutamine-induced wall motion abnormalities are pre-
dictors of cardiac events at follow-up;
2) the presence of contractile reserve at a low dose of
dobutamine is not associated with a worse outcome,
unless further deterioration of wall motion does occur at
higher doses (biphasic response); and
3) patients with two or more markers of myocardial isch-
emia during dobutamine stress test have a higher inci-
dence of cardiac events compared with patients with
more than two ischemic markers.
In this group of patients with a first uncomplicated AMI
and preserved LV function, the presence of residual myo-
cardial ischemia as documented by worsening of wall
motion during DE emerged as the most important prog-
nostic factor of adverse outcome. This is in agreement with
the findings from the Echocardiography Persantine Inter-
national Cooperative study, where dipyridamole echocardi-
ography added significant prognostic information on top of
clinical and exercise ECG test data (8). In the present study,
the prognostic value of DE was similar in patients with
homozonal compared with remote ischemia. Remote isch-
emia at DE is a marker of multivessel disease (9) and, at
least in a recent study, was found to be a predictor of poor
Figure 1. Multivariate predictors of all cardiac events (death,
myocardial infarction or unstable angina) and hard cardiac events
(death or myocardial infarction) after uncomplicated AMI. The
risk associated with a given variable is espressed by a relative risk
(RR) with corresponding 95% confidence intervals. DE 5 dobut-
amine echocardiography.
Figure 2. Incidence of cardiac events (death, myocardial infarction
or unstable angina) during follow-up as a function of the number
(no, one, two or three) of ischemic markers (wall motion abnor-
malities, S-T segment depression or angina) during dobutamine
stress test.
Table 2. Comparison of Patients With and Without Cardiac Events (Univariate Analysis)
Variable
All Hard
Events
(n 5 40)
No events
(n 5 205) p-value
Events
(n 5 16)
No events
(n 5 229) p-value
Age 61 6 7 59 6 10 NS 64 6 5 59 6 10 0.032
Gender 31 (77%) 179 (87%) NS 12 (75%) 198 (86%) NS
Hypertension 10 (25%) 58 (28%) NS 2 (12%) 66 (29%) NS
Diabetes 8 (20%) 18 (9%) 0.035 2 (12%) 24 (10%) NS
Thrombolysis 20 (50%) 98 (48%) NS 6 (37%) 112 (49%) NS
Site of infarction 17 (42%) 86 (42%) NS 6 (37%) 97 (42%) NS
Rest WMSI 1.41 6 0.28 1.41 6 0.30 NS 1.47 6 0.21 1.41 6 0.30 NS
Peak WMSI 1.59 6 0.28 1.54 6 0.34 NS 1.65 6 0.20 1.54 6 0.33 NS
Ischemic WMSI 0.11 6 0.17 0.20 6 0.22 0.004 0.12 6 0.18 0.25 6 0.17 0.005
Viability 15 (37%) 58 (28%) NS 5 (31%) 68 (30%) NS
Positive DE 26 (65%) 89 (43%) 0.005 13 (81%) 102 (44%) 0.0009
Dobutamine time 23 6 4 23 6 4 NS 23 6 4 22 6 5 NS
Remote ischemia 9 (22%) 36 (18%) NS 4 (25%) 41 (17%) NS
Angina during DE 12 (30%) 35 (17%) 0.057 4 (25%) 43 (19%) NS
ECG during DE 13 (32%) 57 (28%) NS 6 (37%) 64 (28%) NS
DE 5 dobutamine echocardiography; ECG 5 electrocardiogram; WMSI 5 wall motion score index.
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prognosis after AMI (10). However, we considered
dobutamine-induced wall motion abnormalities as an end
point, thus limiting the power of the test for detecting
multivessel disease.
The prognostic value of viable myocardium after an AMI
has been questioned. Previous reports suggested that the
evidence of dysfunctioning but viable myocardium after
AMI might be an adverse prognostic factor, acting as an
“unstable substrate” for recurrent myocardial ischemia or
life-threathening arrhythmias (11–13). Recently, and in
contrast with this observation, lack of functional viability
has been associated with adverse outcome (10,14). In the
present study, myocardial viability did not show an inde-
pendent prognostic value. These controversial results can be
explained by the following considerations: 1) the different
echocardiographic criteria of myocardial viability and clini-
cal end points adopted in the different studies; 2) the high
prevalence of biphasic response and the findings at multi-
variate analysis in the present study indicate that, in patients
with a well-preserved LV function, the prognostic impor-
tance of myocardial viability can be obscured by the impact
of ischemia; this is also reported in a recent study in patients
with a first AMI treated with thrombolysis, where myocar-
dial viability did not show an independent prognostic value
(15); 3) remote ischemia may offset the prognostic signifi-
cance of myocardial viability within the infarct zone; and 4)
the beneficial effect of myocardial viability can be more
evident in patients with global LV dysfunction (16) rather
than in patients with a preserved LV function as those
represented in the present study.
In stress echocardiography, the typical marker of myo-
cardial ischemia is considered to be the deterioration of wall
motion, with S-T segment depression or angina as nonspe-
cific and neglectable markers. The results of the present
study indicate that considering all the markers enhances the
prognostic power of dobutamine stress test, with a two-fold
increase in cardiac events at follow-up in patients with two
or more markers compared with patients with one or no
markers. This finding is consistent with previous data
demonstrating the prognostic importance of chest pain and
ECG changes during pharmacologic stress echocardiogra-
phy (8,15,17). However, whether the test should be contin-
ued beyond one significant marker end point is reached has
not been investigated either in terms of safety or prognostic
power.
Risk stratification after AMI. In patients with an AMI, a
set of clinical findings are used as a signal of increased risk
for recurrent cardiac events. These findings include clinical
evidence of pump dysfunction, recurrent ischemia and
high-risk arrhythmias, which dictate for prompt cardiac
catheterization. Patients with intermediate/low risk (that is,
patients who lack these features) are usually referred for
predischarge stress testing, with the challenge to distinguish
the few patients at higher risk from the many relatively
low-risk patients.
In the present study, we assessed the prognostic value of
the predischarge dobutamine stress test to establish whether
it provides additional information beyond the known clin-
ical information in patients with an uncomplicated AMI.
When multivariate analysis was applied to the different
clinical data, the only independent prognostic variables were
age and diabetes. These factors have been already recog-
nized as “not low-risk factors” in a previous study (18).
Our results point out that in a group of patients recov-
ering from an AMI with an uncomplicated course and with
an overall a priori good outcome, this clinical information
alone can efficiently identify low- (no clinical risk factor)
and high- (both clinical risk factors) risk patients. In
patients with an intermediate risk at clinical judgment (only
one clinical risk factor), a dobutamine stress test can be
applied as an adjunctive useful risk stratification tool (Fig.
3). Based on the results of multivariate analysis, age and
diabetes were considered for risk stratification on clinical
ground: patients .60 years with a history of diabetes had a
3.4-fold increase of cardiac events at follow-up compared
with patients ,60 years with no history of diabetes (37% vs.
11%). The presence of only one of the two clinical risk
factors identified a group of patients with an intermediate
risk (18%). In this subgroup of patients, the response at
dobutamine stress test can be used to distinguish patients at
different risk of future cardiac events (10% in patients with
negative DE; 25% in patients with positive DE and no
angina during the test; 35% in patients with positive DE
and angina during the test).
Clinical implications. The optimal risk stratification of
patients after an AMI is still uncertain (19,20). We believe
that in patients without contraindications and who can
exercise, predischarge exercise testing is still the test of
choice, due to its large availability and the solid prognostic
data obtained so far. In patients who are not able to exercise,
Figure 3. Incidence of cardiac events (death, myocardial infarction
or unstable angina) in patients after uncomplicated acute myocar-
dial infarction, according to the presence of clinical risk factors and
the response at dobutamine stress test. DE 5 dobutamine echo-
cardiography.
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with nondiagnostic or inconclusive exercise test, DE is an
attractive and useful alternative, which should be imple-
mented in all echocardiographic laboratory. In our experi-
ence, careful selection of patients with AMI and adaptation
of simple criteria for interruption of the test make predis-
charge DE a safe procedure.
In the present study, age and a history of diabetes
emerged as important clinical predictors of adverse out-
come; dobutamine stress test added independent and prog-
nostically more important variables through the presence of
wall motion abnormalities and angina during dobutamine
infusion. Thus, the integration of the echocardiographic
results with simple clinical (age, diabetes) and dobutamine
stress test variables (angina) refines the interpretation of the
test and may guide cardiologists to optimal clinical decision
making.
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